Pubertal and postpubertal cadmium exposure differentially affects the hypothalamic-pituitary-testicular axis function in the rat.
The effects of administration of cadmium on levels of hormones along the hypothalamic-pituitary-testicular axis were studied in rats. Male rats were treated subcutaneously from days 30 to 60 (pubertal rats) or from days 60 to 90 of life (postpubertal rats), with cadmium chloride (CdCl2) at a dose of 0.5 or 1 mg/kg, every 4 days in an alternate schedule, starting from the lower dose. Age-matched control rats received 0.3 m of saline subcutaneously every 4 days. The levels of norepinephrine (NE) increased on cadmium exposure in pubertal rats in all hypothalamic areas studied, but decreased in the median eminence. In contrast, in postpubertal rats the levels of NE only did not decrease in the posterior hypothalamus. Serotonin (5-HT) concentration in pubertal and postpubertal rats decreased in all hypothalamic regions, while serotonin turnover (measured by the ratio 5-hydroxyindolacetic acid/serotonin [5-HIAA/5-HT]) increased in the anterior hypothalamus. The serotonin metabolism was also increased in the median eminence in the pubertal and in the posterior hypothalamus in the postpubertal rats. Plasma levels of luteinizing hormone (LH) were not modified by cadmium in both age groups, but follicle stimulating hormone (FSH) levels decreased in postpubertal rats, but was not altered in pubertal rats. Plasma levels of testosterone increased in pubertal rats but decreased in postpubertal rats. Cadmium accumulation increased in the hypothalamus and testes in all the cadmium-treated animals, whereas in the pituitary accumulation of cadmium was found only in postpubertal rats. These data suggest that cadmium exerts age-dependent effects on the hypothalamic-pituitary-testicular axis function, and a disruption of the regulatory mechanisms of the hypothalamic-pituitary-gonadal axis emerges.
Lafuente
A
A
Laboratorio de Toxicología, Facultad de Ciencias, Universidad de Vigo, Orense, Spain. lafuente@uvigo.es
Márquez
N
N
Pérez-Lorenzo
M
M
Pazo
D
D
Esquifino
A I
AI
D000818:Animals; D002104:Cadmium / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D004298:Dopamine / Q000378:metabolism; D005640:Follicle Stimulating Hormone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000254:growth & development / Q000378:metabolism / Q000473:pathology*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000378:metabolism; D012741:Sexual Maturation / Q000502:physiology; D013737:Testis / Q000254:growth & development / Q000378:metabolism / Q000473:pathology*; D013739:Testosterone / Q000097:blood; D015430:Weight Gain / Q000187:drug effects
D002104:Cadmium; D012701:Serotonin; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D004298:Dopamine; D009638:Norepinephrine